Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Non-insulin antihyperglycemic drugs · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Toujeo - insulin glargine (U300) | EXPERIMENTAL | Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks |
| Lantus - insulin glargine | ACTIVE_COMPARATOR | Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks |
| Name | Type | Description |
|---|---|---|
| Insulin glargine (U300) | DRUG | Pharmaceutical form: solution Route of administration: subcutaneous |
| Insulin glargine | DRUG | Pharmaceutical form: solution Route of administration: subcutaneous |
| Non-insulin antihyperglycemic drugs | DRUG | Pharmaceutical form: capsule/tablet Route of administration: oral |
Inclusion criteria : * Adult patients with type 2 diabetes mellitus inadequately controlled with non-insulin antihyperglycemic drug(s). * Signed written informed consent. Exclusion criteria: * Age \< legal age of adulthood. * HbA1c \<7.0% (\<53 mmol/mol) or \>11% (\>97 mmol/mol) (at screening). *...
Non-insulin antihyperglycemic drugs are used for the treatment of Type 2 Diabetes Mellitus. This small molecule therapy is being developed by Sanofi and is currently in Phase 3 clinical development for this metabolic condition.
Sanofi (ticker: SNY) is developing Non-insulin antihyperglycemic drugs. The therapy is a small molecule intended for the treatment of Type 2 Diabetes Mellitus and is currently in Phase 3 clinical development.
Non-insulin antihyperglycemic drugs is in Phase 3 clinical development. It is an investigational therapy for Type 2 Diabetes Mellitus and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Non-insulin antihyperglycemic drugs has one completed Phase 3 trial, NCT02855684, which compared the efficacy and safety of a new formulation of insulin glargine with Lantus in patients with Type 2 Diabetes insufficiently controlled with non-insulin antidiabetic therapy. The trial enrolled 604 participants in China, South Korea, and Taiwan.
Non-insulin antihyperglycemic drugs is not the same as insulin glargine. The Phase 3 trial NCT02855684 evaluated a new formulation of insulin glargine against Lantus in patients with Type 2 Diabetes who were insufficiently controlled with non-insulin antihyperglycemic drugs, which refers to the background therapy, not the investigational drug itself.